CBER Reorganization Aims To Fight Recruitment Challenges, Tackle Upcoming Gene Therapy Wave

 
• By Derrick Gingery

A growing focus on real-world evidence and an expected infusion of user fee funding are among the reasons for the new office branches at US FDA’s biologics center.

CBER reorg
CBER added a Division of Human Capital as part of its organizational changes. • Source: Nielsen Hobbs; the Pink Sheet | Alamy image

More from US FDA

More from Agency Leadership